What Incyte Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 20 | 47 |
| Total trades | 52 | 160 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 74,887 | 625,496 |
| Disposed | 126,040 | 689,378 |
| Net activity | −51,153 | −63,882 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Cagnoni Pablo J | President, Global Head of R&D | Oct 15 | Open-market sale · S | −2,642 | $112.71 | −$298K | 183,200 |
| Cagnoni Pablo J | President, Global Head of R&D | Oct 15 | Exercise / conversion · M | +925 | $64.25 | +$59.4K | 185,842 |
| Cagnoni Pablo J | President, Global Head of R&D | Oct 15 | Exercise / conversion · M | +455 | $61.18 | +$27.8K | 184,917 |
| Cagnoni Pablo J | President, Global Head of R&D | Oct 15 | Exercise / conversion · M | +423 | $61.76 | +$26.1K | 184,462 |
| Cagnoni Pablo J | President, Global Head of R&D | Oct 15 | Exercise / conversion · M | +839 | $71.93 | +$60.3K | 184,039 |
| Heeson Lee | EVP, Head of Incyte Intl | Oct 01 | Withheld — tax / exercise cost · F | −463 | $117.14 | −$54.2K | 37,578 |
| Harrigan Edmund | Director | Sep 30 | Grant / award · A | +206 | $121.35 | +$25K | 23,225 |
| Clancy Paul J | Director | Sep 30 | Grant / award · A | +203 | $121.35 | +$24.6K | 25,838 |
| Baker Bros. Advisors Lp | Director | Sep 30 | Grant / award · A | +322 | — | — | 28,206,082 |
| Baker Bros. Advisors Lp | Director | Sep 30 | Grant / award · A | +322 | — | — | 2,835,403 |
| Gardner David H | EVP, Chief Strategy Officer | Sep 22 | Withheld — tax / exercise cost · F | −920 | $126.93 | −$117K | 15,904 |
| Cagnoni Pablo J | President, Global Head of R&D | Sep 15 | Open-market sale · S | −13,985 | $120.49 | −$1.69M | 183,200 |
| Cagnoni Pablo J | President, Global Head of R&D | Sep 15 | Open-market sale · S | −9,233 | $120.50 | −$1.11M | 197,185 |
| Cagnoni Pablo J | President, Global Head of R&D | Sep 15 | Exercise / conversion · M | +9,233 | $71.93 | +$664K | 206,418 |
| Cagnoni Pablo J | President, Global Head of R&D | Sep 15 | Exercise / conversion · M | +6,477 | $64.25 | +$416K | 197,185 |
| Cagnoni Pablo J | President, Global Head of R&D | Sep 15 | Exercise / conversion · M | +4,551 | $61.18 | +$278K | 190,708 |
| Cagnoni Pablo J | President, Global Head of R&D | Sep 15 | Exercise / conversion · M | +2,957 | $61.76 | +$183K | 186,157 |
| Basi Ramitpal K | EVP, Human Resources | Aug 25 | Withheld — tax / exercise cost · F | −504 | $129.72 | −$65.4K | 10,993 |
| Cagnoni Pablo J | President, Global Head of R&D | Aug 19 | Open-market sale · S | −10,801 | $125.56 | −$1.36M | 183,200 |
| Cagnoni Pablo J | President, Global Head of R&D | Aug 12 | Open-market sale · S | −10,803 | $120.04 | −$1.3M | 194,001 |
Loading...